Page 16 of 154: studies 151 to 160 of 1,534, newest first. Back to the ketamine for depression overview
May 27, 2026 James Phelps
A new randomized trial found serial intravenous ketamine was not significantly more effective than the active placebo midazolam in reducing depressive symptoms or improving quality of life. While the study may have been underpowered due to a small sample size (n=63), the improvement in MADRS scores fell short of the minimal clinically important difference. The study faced blinding failures,...
Expert Opin Investig Drugs May 26, 2026 Mina Takahashi, Richard C. Shelton
INTRODUCTION: Bipolar depression with acute suicidal ideation and behavior (ASIB) is a life- threatening manifestation of bipolar disorder (BD), with a suicide risk higher than that in other psychiatric disorders and the general population. Rapid and effective interventions are critical, as traditional therapies are often slow and frequently insufficient. Currently, no drug is approved by the...
Biomedicines May 23, 2026 Dominik Jucha, Michał Klimas, Dominika Wiśniewska et al.
Background/Objectives: Bipolar disorder affects about 40 million people worldwide, and the greatest burden of the disease is associated with depressive episodes. About 25% of patients experience drug-resistant depression, in which standard treatment turns out to be insufficient, and monotherapy often does not bring full remission. Despite the use of second-generation antipsychotics, the...
Psychopharmacology (Berl) May 22, 2026 Wei-Chen Lin, Li-Kai Cheng, Tung-Ping Su et al.
Background: Studies have demonstrated that subanesthetic-dose ketamine may modulate the functioning of specific depression-related brain regions, particularly the anterior cingulate cortex and prefrontal cortex. However, how subanesthetic-dose ketamine alters the global and regional graph theory metrics of resting-state functional connectivity in patients with treatment-resistant depression...
Ther Adv Psychopharmacol May 22, 2026 Liliana Patarroyo-Rodriguez, Vanessa K. Pazdernik, Jennifer L. Vande Voort et al.
Background: Ketamine and esketamine ((es)ketamine) rapidly reduce depressive symptoms and suicidal ideation (SI) in treatment-resistant depression (TRD), but whether early SI improvement during the acute phase of the treatment predicts reduced suicide-associated emergency department (SAED) visits over the longer term remains unclear. Objectives: To examine whether early improvements in SI,...
Scientific Reports May 20, 2026 Guan-Jie She, Wei-Chi Li, Chun-Hsiang Chou et al.
Emerging evidence shows that ketamine, an N-methyl-D-aspartate (NMDA) receptor antagonist, can produce rapid anti-suicidal effects in treatment-resistant depression, yet its underlying neuropharmacological mechanisms remain elusive. The present study aimed at investigating the therapeutic effect of ketamine infusion on suicidal ideation by examining hemodynamic response changes in resting-state...
Pharmacological reports : PR May 20, 2026 Aleksander Kwaśny, Alina Wilkowska, Michał Pastuszak et al.
Background: Treatment-resistant depression (TRD) poses a significant therapeutic challenge, with remission often unattainable. Recognition and detection of treatment-emergent adverse events (TEAEs) are essential, as these events may significantly influence the quality of treatment response. This knowledge aids in personalizing care and selecting the best treatment strategy. Methods: In a...
Therapeutic Advances in Psychopharmacology May 19, 2026 correction
[This corrects the article DOI: 10.1177/20451253261437597.].
Journal of Affective Disorders May 16, 2026 David S. Mathai, Madeleine Cluck, Amna M. Aslam et al. 1 citation
Background: Off-label use of intravenous ketamine (IVK) for depression is a widespread practice with limited regulation in the United States. There is an urgent need for current, evidence-informed treatment guidelines to facilitate patient safety, clinical decision-making, and care quality in real-world contexts. Methods: The American Society of Ketamine Physicians, Psychotherapists and...
Asian Journal of Psychiatry May 16, 2026 Sonia Shenoy, Vijetha Shenoy Belle, Ravindra Neelakanthappa Munoli et al. 1 citation
Background: Oral ketamine is a novel treatment for management of depression. However, evidence related to its effectiveness and safety is unavailable. This systematic review aimed to assess the short-term efficacy and safety of oral ketamine compared to placebo or other modes of ketamine in randomized controlled trials (RCT) in unipolar depression, bipolar depression, and treatment-resistant...